Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176–2184

Article  CAS  PubMed  Google Scholar 

Falanga A, Marchetti M (2014) Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 40(3):348–358

Article  PubMed  Google Scholar 

Noseworthy PA, Kaufman ES, Chen LY, Chung MK, Elkind MSV, Joglar JA et al (2019) Subclinical and device-detected Atrial Fibrillation: pondering the knowledge gap: a Scientific Statement from the American Heart Association. Circulation 140(25):e944–e63

Article  PubMed  PubMed Central  Google Scholar 

Vermond RA, Crijns HJ, Tijssen JG, Alings AM, Van den Berg MP, Hillege HL et al (2014) Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace 16(10):1417–1425

Article  PubMed  Google Scholar 

Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al (2014) Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 174(1):107–114

Article  PubMed  PubMed Central  Google Scholar 

Leiva O, Hobbs G, Ravid K, Libby P (2022) Cardiovascular Disease in Myeloproliferative Neoplasms. JACC: CardioOncology 4(2):166–182

PubMed  PubMed Central  Google Scholar 

Mahe K, Delluc A, Chauveau A, Castellant P, Mottier D, Dalbies F et al (2018) Incidence and impact of atrial arrhythmias on thrombotic events in MPNs. Ann Hematol 97(1):101–107

Article  CAS  PubMed  Google Scholar 

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263–272

Article  PubMed  Google Scholar 

Friberg L, Rosenqvist M, Lip GY (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the swedish atrial fibrillation cohort study. Eur Heart J 33(12):1500–1510

Article  PubMed  Google Scholar 

Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E et al (2013) CHADS(2), CHA(2)S(2)DS(2)-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 80(11):1009–1017

Article  CAS  PubMed  Google Scholar 

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093–1100

Article  PubMed  Google Scholar 

Leiva O, Jenkins A, Rosovsky RP, Leaf RK, Goodarzi K, Hobbs G (2022) Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation. J Cardiol.

Matetic A, Mohamed MO, Essien UR, Guha A, Elkaryoni A, Elbadawi A et al (2023) Association between cancer, CHA2DS2VASc risk, and in-hospital ischaemic stroke in patients hospitalized for atrial fibrillation. Eur Heart J - Qual Care Clin Outcomes.

Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE (2017) Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol 24(14):1555–1566

Article  PubMed  PubMed Central  Google Scholar 

Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T (2019) A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 19(1):184

Article  PubMed  PubMed Central  Google Scholar 

Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal Renal/Liver function, stroke, bleeding history or predisposition, labile INR, Elderly, Drugs/Alcohol concomitantly) score. J Am Coll Cardiol 57(2):173–180

Article  CAS  PubMed  Google Scholar 

Kc D, Falchi L, Verstovsek S (2017) The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol 96(10):1595–1604

Article  PubMed  Google Scholar 

Didisheim P, Bunting D (1966) Abnormal platelet function in myelofibrosis. Am J Clin Pathol 45(5):566–573

Article  CAS  PubMed  Google Scholar 

Matsuura S, Thompson CR, Belghasem ME, Bekendam RH, Piasecki A, Leiva O et al (2020) Platelet dysfunction and thrombosis in JAK2(V617F)-Mutated primary myelofibrotic mice. Arterioscler Thromb Vasc Biol. :ATVBAHA120314760

Dubois A, Dauzat M, Pignodel C, Pomier-Layrargues G, Marty-Double C, Lopez FM et al (1993) Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations. Hepatology 17(2):246–250

Article  CAS  PubMed  Google Scholar 

Palandri F, Polverelli N, Catani L, Sollazzo D, Ottaviani E, Parisi S et al (2012) Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. Br J Haematol 156(2):281–284

Article  CAS  PubMed  Google Scholar 

Baysal M, Bayrak M, Eskazan AE (2023) Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert Rev Hematol 16(2):131–140

Article  CAS  PubMed  Google Scholar 

Herbreteau L, Papageorgiou L, Le Clech L, Garcia G, James C, Pan-Petesch B et al (2022) Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms. Thromb Res 216:25–34

Article  CAS  PubMed  Google Scholar 

How J, Story C, Ren S, Neuberg D, Rosovsky RP, Hobbs GS et al (2021) Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J 11(11):176

Article  PubMed  PubMed Central  Google Scholar 

Tsigkas G, Apostolos A, Despotopoulos S, Vasilagkos G, Kallergis E, Leventopoulos G et al (2022) Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions. Heart Fail Rev 27(4):1201–1210

Article  PubMed  Google Scholar 

Leiva O, Ren S, Neuberg D, Bhatt A, Jenkins A, Rosovsky R et al (2022) Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease. Int J Hematol.

Leiva O, Bhatt A, Jenkins A, Rosovsky R, Karp-Leaf R, Goodarzi K et al (2021) Abstract 10079: risk of Cardiovascular and all-cause mortality in patients with myeloproliferative neoplasms following heart failure hospitalization. Circulation 144(Suppl1):A10079–A

Google Scholar 

Wu J, Zhang L, Vaze A, Lin S, Juhaeri J (2015) Risk of Wernicke’s encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. Cancer Epidemiol 39(2):242–249

Article  PubMed  Google Scholar 

Sano S, Wang Y, Yura Y, Sano M, Oshima K, Yang Y et al (2019) JAK2 (V617F) -Mediated clonal hematopoiesis accelerates pathological remodeling in Murine Heart failure. JACC Basic Transl Sci 4(6):684–697

Article  PubMed  PubMed Central  Google Scholar